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Abstract. 
 
To examine the role of mitogen-activated 
 
protein kinase and nuclear factor kappa B (NF-
 
k
 
B) 
pathways on osteoclast survival and activation, we con-
structed adenovirus vectors carrying various mutants of 
 
signaling molecules: dominant negative Ras (Ras
 
DN
 
), 
constitutively active MEK1 (MEK
 
CA
 
), dominant nega-
tive I
 
k
 
B kinase 2 (IKK
 
DN
 
), and constitutively active 
IKK2 (IKK
 
CA
 
). Inhibiting ERK activity by Ras
 
DN
 
 over-
expression rapidly induced the apoptosis of osteoclast-
like cells (OCLs) formed in vitro, whereas ERK activa-
tion after the introduction of MEK
 
CA
 
 remarkably 
lengthened their survival by preventing spontaneous 
apoptosis. Neither inhibition nor activation of ERK af-
fected the bone-resorbing activity of OCLs. Inhibition 
of NF-
 
k
 
B pathway with IKK
 
DN
 
 virus suppressed the 
pit-forming activity of OCLs and NF-
 
k
 
B activation by 
IKK
 
CA
 
 expression upregulated it without affecting their 
survival. Interleukin 1
 
a
 
 (IL-1
 
a
 
) strongly induced ERK 
activation as well as NF-
 
k
 
B activation. Ras
 
DN
 
 virus par-
tially inhibited ERK activation, and OCL survival pro-
moted by IL-1
 
a
 
. Inhibiting NF-
 
k
 
B activation by IKK
 
DN
 
 
virus signiﬁcantly suppressed the pit-forming activity 
enhanced by IL-1
 
a
 
. These results indicate that ERK 
and NF-
 
k
 
B regulate different aspects of osteoclast acti-
vation: ERK is responsible for osteoclast survival, 
whereas NF-
 
k
 
B regulates osteoclast activation for bone 
resorption.
Key words:  osteoclast • adenovirus • apoptosis • Ras 
• NF-
 
k
 
B
 
Introduction
 
Osteoclasts, multinucleated giant cells responsible for
bone resorption, are terminally differentiated cells with a
short life span. Recent findings suggest that the survival of
osteoclasts is precisely regulated through interactions with
 
supporting cells as well as by the action of several cytokines
(Fuller et al., 1993; Jimi et al., 1995; Hughes et al., 1996;
Selander et al., 1996; Kameda et al., 1997). However, the
detailed molecular events implicated in these processes still
remain elusive.
The small GTP-binding protein Ras is ubiquitously
found in eukaryotic organisms and functions as an inducer
of various intracellular signaling pathways including cell
proliferation and differentiation (Bourne et al., 1990; Bol-
lag and McCormick, 1991; Kaziro et al., 1991). This cas-
cade can be activated by a variety of receptors (Chambard
et al., 1987; L’Allemain et al., 1991; Ahn et al., 1992) and
leads to activation of mitogen-activated protein kinase
(MAPK)
 
1
 
 cascades. Upon stimulation, Ras assumes its ac-
tive GTP-bound form, and recruits the protein kinase Raf-1
to the plasma membrane, where the kinase can be activated
(Leevers et al., 1994; Stokoe et al., 1994). Raf-1 stimulates
MAP kinase kinases (MEK1 and MEK2), which in turn
activate ERK1 (p44MAPK) and ERK2 (p42MAPK) (Ky-
riakis et al., 1992). Although the Ras/ERK pathway is re-
ported to be an important component of cell survival sig-
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Abbreviations used in this paper:
 
 
 
a
 
-MEM, 
 
a
 
-modified minimum essential
medium; CSF, colony stimulating factor; EMSA, electrophoretic mobility
shift assay; ERK, extracellular signal-regulated kinase; IKK, I
 
k
 
B kinase;
IL-1
 
a
 
, interleukin 1
 
a
 
; MAPK, mitogen-activated protein kinase; MEK,
MAPK/ERK kinase; MOI, multiplicity of infection; NF-
 
k
 
B, nuclear factor
kappa B; OCLs, osteoclast-like cells; TUNEL, Tdt-mediated dUTP dioxi-
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nal in hematopoietic cells (Kinoshita et al., 1997), its exact
role in osteoclasts has not been characterized.
Nuclear factor kappa B (NF-
 
k
 
B) is a transcription factor
that regulates the expression of many genes involved in
immune and inflammatory responses (Siebenlist et al.,
1994; Baldwin, 1996). Activation of NF-
 
k
 
B is controlled by
sequential phosphorylation, ubiquitination, and degrada-
tion of its inhibitory subunit, I
 
k
 
B. A large multiprotein
complex, the I
 
k
 
B kinase (IKK) signalsome, was found to
contain a cytokine-inducible I
 
k
 
B kinase activity that phos-
phorylates I
 
k
 
B-
 
a
 
 and I
 
k
 
B-
 
b
 
. The functional IKK complex
contains IKK1 (IKK
 
a
 
), IKK2 (IKK
 
b
 
), and IKK
 
g
 
, and
both IKK1 and IKK2 appear to make an essential contri-
bution to I
 
k
 
B phosphorylation. Mercurio et al. (1997) re-
ported that Ser177 and Ser181 to Ala mutant of IKK2 in-
hibited NF-
 
k
 
B activation induced by TNF-
 
a
 
, whereas
Ser177 and Ser181 to Glu mutant induced constitutive ac-
tivation of NF-
 
k
 
B. It was recently reported that mice defi-
cient in both the p50 and p52 subunits of NF-
 
k
 
B fail to
generate mature osteoclasts and exhibit severe osteopetro-
sis (Franzoso et al., 1997; Iotsova et al., 1997). Jimi et al.
(1998) also reported the involvement of NF-
 
k
 
B pathways
in the survival of osteoclasts promoted by interleukin 1
(IL-1). These results suggest that the NF-
 
k
 
B pathway is
important for both the differentiation of osteoclast precur-
sors and the survival of mature osteoclasts.
We recently reported that adenoviral vectors are useful
for modulating osteoclast function by transducing foreign
genes into osteoclasts (Tanaka et al., 1998). Using this sys-
tem as well as specific inhibitors, we investigated the role
of ERK pathways and NF-
 
k
 
B pathways in the survival and
activation of osteoclasts, and found that the ERK activa-
tion is essential in maintaining osteoclast survival as is the
NF-
 
k
 
B pathway for upregulation of bone-resorbing activ-
ity of osteoclasts.
 
Materials and Methods
 
Animals and Chemicals
 
Newborn ddY mice and 8-wk-old male ddY mice were purchased from
Shizuoka Laboratories Animal Center. 
 
a
 
-Modified minimum essential
medium (
 
a
 
MEM) and DME were purchased from GIBCO BRL and Life
Technologies Inc., and FBS was purchased from Cell Culture Laboratory.
Bacterial collagenase and 1
 
a
 
,25-dihydroxyvitamin D
 
3
 
 (1
 
a
 
,25(OH)
 
2
 
D
 
3
 
)
were purchased from Wako Pure Chemical Co., and dispase from Godo
Shusei Co. MEK inhibitor PD98059, anti–phospho-ERK and anti–I
 
k
 
B-
 
a
 
antibodies were purchased from New England Biolabs, Inc., anti–v-src an-
tibody (clone 327) from Oncogene Research Products, anti–Flag antibody
from Sigma Chemicals, and anti–NF-
 
k
 
B (p65) antibody from Santa Cruz
Biotechnology. Anti–Ras, anti–MEK1, and anti–ERK antibodies were
obtained from Transduction Laboratories. Other chemicals and reagents
used in this study were of analytical grade.
 
Cells and Cell Cultures
 
Mouse primary osteoblastic cells were obtained from 1-d-old ddY mouse
calvaria by enzymatic digestion, and bone marrow cells were from tibiae
of 8-wk-old male ddY mice (Takahashi et al., 1988). Osteoblastic cells (5 
 
3
 
10
 
5
 
 cells/dish) were cocultured with bone marrow cells (10
 
7
 
 cells/dish) on
10-cm dishes or collagen gel-coated dishes in the presence of 10 nM
1
 
a
 
,25(OH)
 
2
 
D
 
3
 
 and 1 
 
m
 
M PGE
 
2
 
 as previously reported (Akatsu et al.,
1992). For protein analysis, osteoclast-like cells (OCLs) were purified af-
ter a modification of the method originally reported by Tezuka et al.
(1992). In brief, the crude osteoclast preparation placed on plastic dishes
was washed with 
 
a
 
MEM, and treated with 5 ml of 
 
a
 
MEM containing
0.1% collagenase and 0.2% dispase for 10 min to remove osteoblastic
 
cells. The purity of OCLs and their precursors was 
 
.
 
90% at the final
preparation (Tanaka et al., 1995).
 
Constructs and Gene Transduction
 
The recombinant adenovirus vector carrying either dominant negative
Ras (Ser17 to Asn, AxRas
 
DN
 
), constitutively active MEK1 (Ser218 and
Ser222 to Glu, AxMEK
 
CA
 
), dominant negative IKK2 (also called IKK
 
b
 
)
(Ser177 and Ser181 to Ala, AxIKK
 
DN
 
), or constitutively active IKK2
(Ser177 and Ser181 to Glu, AxIKK
 
CA
 
) gene under the control of the CAG
(cytomegalovirus IE enhancer 
 
1
 
 chicken 
 
b
 
-actin promoter 
 
1
 
 rabbit 
 
b
 
-glo-
bin poly (A)
 
1
 
 signal) promoter was constructed by homologous recombi-
nation between the expression cosmid cassette and the parental virus ge-
nome in 293 cells as described (Niwa et al., 1991; Miyake et al., 1996); the
control virus (Ax1w1) was provided by Dr. Izumu Saito (The University
of Tokyo, Bunkyo-ku, Tokyo, Japan). Titers of virus stocks were deter-
mined by endpoint cytopathic effect assay with the following modifica-
tions. 50 
 
m
 
l of DME/10%FBS was dispensed into each well of a 96-well
tissue culture plate, and then eight rows of threefold serial dilutions of the
virus starting from 10
 
2
 
4
 
 dilutions were prepared. 3 
 
3 
 
10
 
5
 
 293 cells in 50 
 
m
 
l
of DME/10%FBS was added to each well. The plate was incubated at
37
 
8
 
C in 5% CO
 
2
 
 in air, and 50 
 
m
 
l of DME/10%FBS was added to each well
every 3 d. 12 d later, the endpoint of the cytopathic effect was determined
by microscopy, and the 50% tissue culture infectious dose (TCID
 
50
 
) was
calculated. One TCID
 
50
 
/ml approximately corresponds to one plaque
forming unit (PFU)/ml (Kanegae et al., 1994). The efficiency of infection
is affected not only by the concentration of viruses and cells, but also by
the ratio of viruses to cells, the multiplicity of infection (MOI). In this
study, MOI is expressed as a measure of titer how many PFU are added to
every cell. Infection of adenovirus vectors to OCLs was carried out fol-
lowing the method previously described (Tanaka et al., 1998). In short,
mouse cocultures on day 4, when OCLs began to appear, were incubated
with a small amount of 
 
a
 
MEM containing the recombinant adenoviruses
for 1 h at 37
 
8
 
C at an indicated MOI. The cells were washed twice with PBS
and further incubated with 
 
a
 
MEM/10%FBS at 37
 
8
 
C. Experiments were
performed 24 h after the infection.
 
Western Blotting
 
All extraction procedures were performed at 4
 
8
 
C or on ice. Cells were
washed with ice-cold PBS, and then lysed by adding TNE buffer (1% NP-
40, 10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM EDTA, 2 mM Na
 
3
 
VO
 
4
 
,
10 mM NaF, and 10 
 
m
 
g/ml aprotinin). The lysates were clarified by centrif-
ugation at 15,000 rpm for 20 min. An equal amount (20 
 
m
 
g) of protein was
subjected to 8% SDS-PAGE under a reducing condition, transferred elec-
trophoretically onto a nitrocellulose membrane, and probed sequentially
with an appropriate primary antibody followed by secondary antibodies
coupled with HRP (Promega Corp.). Immunoreactive proteins were visu-
alized using ECL Western blotting detection reagents (Amersham Co.)
following the procedures recommended by the supplier. The blots were
stripped by incubating for 20 min in stripping buffer (2% SDS, 100 mM
2-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.7) at 50
 
8
 
C and reprobed by
other antibodies.
 
Immunoprecipitation and In Vitro Kinase Assay
 
Treated cell cultures were washed twice with ice-cold PBS and lysed in ly-
sis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 12 mM
 
b
 
-glycerophosphate, 5 mM EGTA, 0.5% deoxycholate, 3 mM DTT, 10
mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 2 
 
m
 
M leupeptin, 20 
 
m
 
g/ml aprotinin, and 1 mM
PMSF). After 30 min on ice, cell lysates were cleared by centrifugation at
12,000 
 
g
 
 for 20 min. The protein concentration in each sample was quanti-
fied by the Bradford method, and immunoprecipitation was performed by
incubating 200 
 
m
 
l of lysate with 2 
 
m
 
g of anti–ERK2 (p42) antibody (Santa
Cruz Biotechnology) for 1 h, and then adding 20 
 
m
 
l of protein A–agarose.
After incubation for 1 h at 4
 
8
 
C with end-over-end mixing, the immuno-
complex was recovered by centrifugation and washed with washing buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EGTA, 2 mM DTT, and
1 mM PMSF) twice. Kinase activity was assayed for 20 min at 37
 
8
 
C in the
presence of 6 
 
m
 
g substrate (MBP), 30 
 
m
 
M ATP, and 20 
 
m
 
Ci 
 
g
 
-[
 
32
 
P] ATP in
55 
 
ml assay buffer (20 mM Tris-HCl, pH 7.5, and 20 mM MgCl2). After
completion of kinase assays, the protein was resolved by SDS-PAGE, and
the gels were dried and subjected to autoradiography. The relative activity
of ERK2 was quantified by measuring the radioactivity of phosphorus-32
incorporated into MBP.Miyazaki et al. ERK and NF-kB in Osteoclasts 335
DNA Extraction and Electrophoretic Analysis
DNA was prepared and analyzed by gel electrophoresis according to the
method described previously (Jimi et al., 1998). In brief, purified OCLs
were lysed by incubating at 608C overnight in a digestion buffer containing
150 mM NaCl, 25 mM EDTA, 100 mg/ml proteinase K, and 0.2% SDS.
The DNA was extracted twice with phenol/chloroform/isoamylalcohol
and once with chloroform, and precipitated in ethanol with 150 mM
CH3COONa, pH 5.2. The DNA was dissolved in TE buffer (10 mM Tris-
HCl, pH 8.0, and 1 mM EDTA) and treated with 20 mg/ml RNase A. The
procedure for DNA extraction and precipitation were repeated. 2 mg of
DNA was separated by electrophoresis on a 1.5% agarose gel and visual-
ized by ethidium bromide staining with UV light illumination.
TUNEL Assay
Cells undergoing apoptosis were identified by means of the TdT-mediated
dUTP-dioxigenin nick-end labeling (TUNEL) method, which specifically
labels the 39-hydroxyl terminal of DNA strand breaks. For the TUNEL
procedure, all agents, including buffers, were part of a kit (apoptosis in
situ detection kit; Wako Pure Chemical Co.); the staining procedure was
carried out according to the manufacturer’s recommendation. Negative
controls included omission of TdT. Positive controls included treatment of
the samples with DNase I. Apoptotic cells were recognized by their dark
nuclear staining (TUNEL-positive), and nuclei of nonapoptotic cells were
visualized by staining with methyl green.
Survival of OCLs
The survival rate was measured as reported (Jimi et al., 1998). OCLs were
purified 24 h after the infection and some of the cultures were subjected to
tartrate-resistant acid phosphatase (TRAP) staining. Cell viability/sur-
vival is expressed as morphologically intact TRAP-positive multinucle-
ated cells. Other cultures were further incubated for the indicated times,
and then the number of living OCLs was counted. The number of viable
cells remaining at the different time points is shown as a percentage of the
cells at time zero.
Immunofluorescence Microscopy
For immunofluorescence analysis, cells were plated on sterile FBS-coated
glass coverslips and purified by treatment with aMEM containing 0.1%
collagenase and 0.2% dispase. After purification, OCLs were preincu-
bated for 20 min at 378C in aMEM without FBS and further incubated in
aMEM with IL-1a (10 ng/ml) for indicated times, fixed in PBS containing
4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100
in PBS for 5 min, and then blocked with 5% skim milk in PBS for 20 min
at room temperature. Cells were sequentially stained with anti–p65 anti-
body followed by Cy5-conjugated anti-rabbit IgG (Amersham Co.) as
previously reported (Isshiki et al., 1998). The subcellular localization of
Cy5-labeled p65 was analyzed by a cooled CCD camera (Roper Scien-
tific).
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared as described previously (Jimi et al., 1998).
For samples of purified OCLs, cells were scraped off each dish and put in
ice-cold PBS. The cells were washed in ice-cold PBS, lysed for 10 min in
ice-cold hypotonic buffer (buffer A: 10 mM Hepes, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT, and 0.5 mM PMSF), and lysed for 10 min on ice
in buffer A containing 0.1% NP-40. The lysates were centrifuged for 20 s
at 12,000 g. The pelleted nuclei were resuspended in a high salt lysis buffer
(20 mM Hepes, pH 7.9, 420 mM NaCl, 25% glycerol, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM PMSF, and 0.5 mM DTT), incubated at 48C for 20 min,
supplemented with 5 vol of storage buffer (20 mM Hepes, pH 7.9, 100 mM
KCl, 20% glycerol, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT),
and vortexed for 10 s. Lysed nuclei were centrifuged for 10 min at 12,000 g,
and the resulting supernatants were referred to as nuclear extracts. Oligo-
nucleotide probes containing consensus sequences for NF-kB was pro-
vided by Dr. Jun-Ichiro Inoue (The Institute of Medical Science, The Uni-
versity of Tokyo, Minato-ku, Tokyo, Japan). The DNA binding reaction
was performed at room temperature in a volume of 20 ml, which contained
the binding buffer (25 mM Tris-HCl, pH 7.5, 1.5 mM EDTA, 7.5% glyc-
erol, 75 mM NaCl, 1.5 mM DTT, 0.3% NP-40, and 1 mg/ml BSA), 1 mg of
poly (dI-dC), 105 cpm of 32P-labeled probe, and 8 mg of nuclear proteins.
After incubation for 30 min, the samples were fractionated on a 4% poly-
acrylamide gel and visualized by exposing dried gel to film.
Pit Formation Assay
Functionally active OCLs formed in cocultures were obtained by a col-
lagen gel culture system as described by Akatsu et al. (1992). In brief, pri-
mary osteoblastic cells and bone marrow cells were cocultured in the pres-
ence of 10 nM 1a,25(OH)2D3 and 1 mM PGE2 on culture dishes (6 cm)
coated with 0.2% collagen gel matrix. OCLs 24 h after the infection were
recovered by digesting the collagen gel with 0.2% collagenase for 20 min
at 378C. The cells released from the dishes were collected by centrifuga-
tion at 250 g for 5 min and resuspended in 5 ml of aMEM containing 10%
FBS. An aliquot of the crude OCL preparation was transferred onto den-
tine slices and cultured for an additional 12 h. After 12 h of incubation, the
medium was removed and 1 M NH4OH was added to the wells for 30 min.
Adherent cells were removed from the dentine slices by ultrasonication,
and the resorption pits were visualized by staining with 1% toluidine blue.
The resorbed area was measured using an image analysis system (SYS-
TEM SUPPLY) linked to a light microscope (Nikon).
Statistical Analysis
Each series of experiments was repeated at least three times. The results
obtained from a typical experiment were expressed as the means 6 SD.
Significant differences were determined using factorial analysis of vari-
ance (ANOVA).
Results
Downregulation of Ras Inhibits Osteoclast Survival
Recently, we have reported that a replication-deficient ad-
enovirus vector that contains a reporter gene encoding
b-galactosidase efficiently infected human OCLs derived
from human giant cell tumors and mouse OCLs formed in
vitro (Tanaka et al. 1998). The proportion of b-gal–posi-
tive OCLs increased in accordance with the number of re-
combinant adenoviruses inoculated in the culture, and
.85% of OCLs became strongly positive for b-gal activity
at an MOI of 100, with no obvious morphological change
or toxic effects. As shown in Fig. 1 A, the expression of
RasDN was clearly induced in infected OCLs in an MOI-
dependent manner. The bottom panel shows that an equal
amount of protein was applied in each lane as determined
by the Western blotting of c-Src. We next examined the ef-
fect of RasDN expression on the survival of OCLs. After
the treatment with 0.1% collagenase and 0.2% dispase to
remove osteoblastic cells, noninfected OCLs and OCLs in-
fected with Ax1w1 or AxRasDN at an MOI of 100 were fur-
ther incubated in aMEM containing 10% FBS to deter-
mine their survival. After the removal of osteoblastic cells,
z70% of OCLs infected with or without Ax1w1 died
within 18 h (Fig. 1, D and E). In contrast, almost all the
RasDN-expressed OCLs disappeared within 18 h (Fig. 1, D
and E), indicating a critical role of Ras in the survival of
osteoclasts.
The Deteriorative Effect of RasDN Overexpression Is 
Reversed by AxMEKCA Infection
We next examined the signaling pathways working down-
stream of Ras in osteoclasts. As shown in the top and mid-
dle panels of Fig. 1 C, overexpression of RasDN clearly in-
hibited the basal activity of ERK in OCLs and ERK
activity was z90% downregulated in RasDN-expressed
OCLs at an MOI of 100. To determine whether or notThe Journal of Cell Biology, Volume 148, 2000 336
modulating ERK activity could affect the survival of
OCLs, we used PD98059, a specific inhibitor of ERK acti-
vation that does not affect the activation of other MAPKs
(Alessi et al., 1995; Favata et al., 1998). PD98059 treat-
ment severely diminished the survival of OCLs (Fig. 1
D). Conversely, upregulation of ERK activity in OCLs us-
ing recombinant adenovirus encoding constitutively active
MEK1 (AxMEKCA) remarkably enhanced their survival
(Fig. 1, B–E).
To examine whether or not ERK is the main signaling
pathway working downstream of Ras in osteoclasts, we in-
vestigated the survival of OCLs that were coinfected with
AxRasDN and AxMEKCA. Coinfected OCLs expressed
RasDN and MEKCA at the similar level with the cells in-
fected with either RasDN or MEKCA (Fig. 2 A), and the de-
teriorative effect of AxRasDN on OCLs was completely
rescued by coinfection with AxMEKCA (Fig. 2 B). Nor did
the treatment with PD98059, which suppresses the intrinsic
MEK activation, inhibit the survival of MEKCA-expressed
OCLs (Fig. 2 B). We also found that the expression of
RasDN did not alter the activity of JNK/SAPK or p38 in
OCLs (data not shown). Taken together, these findings
clearly demonstrate that the Ras/ERK pathway is an im-
portant component of survival signal in osteoclasts.
RasDN Expression Causes Apoptosis of Osteoclasts
We next determined if the reduction of OCL survival by
expression of RasDN was due to apoptosis. After purifica-
tion, uninfected OCLs or OCLs infected with Ax1w1,
AxRasDN, or AxMEKCA at an MOI of 100 were cultured
for 12 or 24 h. The cells were harvested, and genomic
DNA was isolated and resolved on 1.5% agarose gel. Af-
ter 12 h of culturing, DNA fragmentation was hardly detect-
able in uninfected OCLs or OCLs infected with Ax1w1,
whereas OCLs infected with AxRasDN clearly showed
DNA fragmentation (Fig. 3 A). This fragmentation was
observed even in uninfected OCLs or OCLs infected with
Ax1w1 after 24 h of culture, and the expression of MEKCA
markedly inhibited the fragmentation (Fig. 3 A). Almost
all the nuclei of MEKCA-expressed OCLs, 24 h after the
purification, were stained uniformly with Hoechst 33258,
which indicates that the cells were alive and the nuclei
Figure 1. Adenovirus vector-induced RasDN or MEKCA expres-
sion in OCLs. OCLs formed on culture dishes were noninfected
or infected with Ax1w1, AxRasDN, or AxMEKCA at indicated
MOIs. MOI is a measure of titer, meaning how many viruses are
infected a cell. After 24 h of infection, OCLs were purified by en-
zymatic digestion and lysed with TNE buffer. The expression of
RasDN (A) or MEKCA (B) increased in proportion to the MOI of
the recombinant adenovirus, whereas the level of c-Src was not
significantly changed upon RasDN or MEKCA induction. (C) Mod-
ulation of ERK activity by adenovirus vector–induced RasDN or
MEKCA. OCLs formed on culture dishes were noninfected or in-
fected with Ax1w1, AxRasDN, or AxMEKCA at an MOI of 100,
and then immunoblotted with anti–phospho-ERK antibody
(middle). The stripped membrane was reprobed with anti–ERK
antibody (bottom). ERK enzymatic activity was determined by
immunocomplex kinase assay with MBP as a substrate (top).
Fold increases in ERK activation are shown above each lane. (D)
Time course of the survival of OCLs. After purification, nonin-
fected OCLs or OCLs infected with Ax1w1, AxRasDN, or
AxMEKCA were incubated with aMEM/10%FBS and nonin-
fected OCLs were incubated in the presence of 40 mM PD98059
for indicated times. The number of viable cells remaining at the
different time points is shown as a percentage of the cells at time
zero. The cell viability rate of OCLs infected with AxRasDN or
treated with PD98059 was significantly lower, and that of
AxMEKCA-infected OCLs is significantly higher at 12, 18, and
24 h than that of control OCLs at 12 and 18 h time points. E
shows typical TRAP stainings of OCLs 18 h after purification by
the experiment described in D.
Figure 2. The deteriorative
effect of RasDN overexpres-
sion is rescued by AxMEKCA
infection. (A) Mouse cocul-
tures on day 4, when OCLs
began to appear, were incu-
bated with a small amount of
aMEM containing AxRasDN
for 1 h at 378C at an MOI of
100, washed twice with PBS,
and incubated with a small
amount of aMEM contain-
ing AxMEKCA for 1 h at 378C
at an MOI of 100. The cells
were washed twice with PBS
again and further incubated
with  aMEM/10%FBS at 378C.
After 24 h of infection, OCLs
coinfected with AxRasDN and
AxMEKCA were purified by
enzymatic digestion and lysed
with TNE buffer. Coinfected
OCLs expressed RasDN and
MEKCA at the similar level
with the cells infected with either AxRasDN or AxMEKCA. (B) Af-
ter purification, OCLs coinfected with AxRasDN and AxMEKCA
were incubated with aMEM/10%FBS, and AxMEKCA-infected
OCLs were incubated in the presence of 40 mM PD98059 for indi-
cated times. The number of viable cells remaining at the different
time points is shown as a percentage of the cells at time zero. The
toxic effects of RasDN or PD98059 were entirely reversed by
MEKCA expression.Miyazaki et al. ERK and NF-kB in Osteoclasts 337
were intact, whereas expression of RasDN caused conden-
sation of .80% of nuclei 12 h after purification (Fig. 3 B).
We further determined that z80% of the nuclei infected
with AxRasDN underwent apoptosis 12 h after the purifica-
tion as shown in Fig. 3 C by TUNEL staining. In contrast,
positive TUNEL staining was hardly observed in MEKCA-
expressed OCLs even 24 h after the purification (Fig. 3 C).
These findings suggest that Ras/ERK pathways contribute
greatly to preventing apoptosis of osteoclasts.
IL-1a Activates ERK in OCLs
IL-1a is a proinflammatory cytokine that strongly pro-
motes the survival of osteoclasts by preventing their apop-
tosis (Jimi et al., 1998). Therefore, we examined the effect
of IL-1a treatment on ERK activity in OCLs. After purifi-
cation, Ax1w1-infected OCLs and RasDN-expressed OCLs
were preincubated for 20 min at 378C in aMEM without
FBS and further incubated in aMEM with IL-1a (10 ng/ml)
for various periods. As shown in the top panel of Fig. 4 A,
Figure 3. RasDN expression stimulates apoptosis
of OCLs. (A) DNA ladder assay for apoptosis.
Fragmentation of DNA in uninfected OCLs and
OCLs infected with Ax1w1 was not detectable
within 12 h, but it was observed after culturing
for 24 h. DNA fragmentation was observed in
RasDN-expressed OCLs within 12 h. In contrast,
expression of MEKCA inhibited ladder formation
of DNA. The 123-bp ladder DNA was used as a
marker. (B) The nuclei of MEKCA-expressed
OCLs 24 h after the purification were stained
uniformly with Hoechst 33258 (bottom),
whereas expression of RasDN caused fragmenta-
tion and condensation of nuclei 12 h after the purification (top). (C) The TUNEL staining of MEKCA- or RasDN-expressed OCLs was
started 24 or 12 h after the purification, respectively. Apoptotic cells were recognized by their dark nuclear staining (TUNEL-positive)
and nuclei of nonapoptotic cells were visualized by staining with methyl green. Bars: (B) 10 mm; (C) 100 mm.
Figure 4. The effects of IL-1a treatment on
RasDN-expressed OCLs. (A, top) Time course of
change in ERK activity in Ax1w1- or AxRasDN-
infected OCLs in response to IL-1a treatment.
(middle) Western blot analysis of the expression
of ERK protein. (bottom) Time course of change
in the protein level of IkB in Ax1w1- or AxRasDN-
infected OCLs. (B) Effects of AxRasDN on the
survival of OCLs promoted by IL-1a. After puri-
fication, Ax1w1- or AxRasDN-infected OCLs
were incubated with aMEM/10%FBS in the
presence of IL-1a (10 ng/ml) for indicated times.
The number of viable cells remaining at different
time points is shown as a percentage of the cells
at time zero. AxRasDN partially inhibited the
promotion of OCL survival induced by IL-1a.
(C) Ax1w1- or AxRasDN-infected OCLs were in-
cubated with 10 ng/ml IL-1a for indicated time
periods. Equivalent amounts of nuclear extract
protein were incubated with a radiolabeled probe
containing NF-kB binding site. Activation of
NF-kB was determined using EMSA. (D) Puri-
fied Ax1w1-infected OCLs or RasDN-expressed
OCLs were treated with IL-1a (10 ng/ml) for 0
or 30 min. Cells were fixed and incubated with
antibodies against p65 followed by Cy5-conju-
gated anti–rabbit immunoglobulins. The subcel-
lular localization of Cy5-labeled p65 (red) was
observed by a cooled CCD camera. To visualize
the nuclei of the OCLs, the cells were further
stained with Hoechst 33258 (blue). Before stimu-
lation, p65 was localized in the cytoplasm, espe-
cially around the nuclei of OCLs infected with
Ax1w1 or AxRasDN. At 30 min, p65 was detected
in most of the nuclei of Ax1w1- or AxRasDN-
infected OCLs in response to IL-1a.The Journal of Cell Biology, Volume 148, 2000 338
IL-1a stimulated a rapid and transient increase in ERK ac-
tivity in OCLs. ERK activation in response to IL-1a was
transient, reaching the highest level after 15–30 min of
stimulation and returning to the basal level after 60 min.
Stimulation of ERK activity was not accompanied by a
change in the expression level of ERK protein (Fig. 4 A,
middle). As previously reported by Jimi et al. (1998), IL-
1a treatment strongly promoted the survival of OCLs (Fig.
4 B). Interestingly, the expression of RasDN in OCLs only
partially inhibited the ERK stimulation induced by IL-1a,
as shown in the top panel of Fig. 4 A, and partially sup-
pressed the promotion of their survival induced by IL-1a
(Fig. 4 B).
RasDN Expression Does Not Affect the IL-1a–induced 
Nuclear Translocation of NF-kB in OCLs
Because activation of NF-kB was reported to be involved
in the survival of osteoclasts promoted by IL-1a (Jimi et al.,
1998), we examined the effect of RasDN protein on the ac-
tivation of NF-kB in response to IL-1a. NF-kB is present
in the cytosol in an inactive state, complexed with the in-
hibitory IkB proteins. Activation occurs via phosphoryla-
tion of IkB-a at Ser 32 and 36, which promotes the degra-
dation of IkB-a, resulting in the dissociation and nuclear
translocation of active NF-kB (Traenckner et al., 1995;
Chen et al., 1996). As shown in the bottom panel of Fig.
4 A by Western blotting, IkB-a expression rapidly de-
creased upon IL-1a stimulation and returned to the basal
level after 60 min of stimulation in Ax1w1-infected OCLs.
The bottom panel of Fig. 4 A shows that RasDN expression
in OCLs did not affect the kinetics of the degradation of
IkB-a by IL-1a. The change in the localization of NF-kB
in OCLs treated with IL-1a was also examined immunocy-
tochemically using specific antibodies against the p65 sub-
unit of NF-kB. Before stimulation, p65 was diffusely dis-
tributed throughout the cytoplasm. Consistent with the
previous report (Jimi et al., 1998), when purified Ax1w1-
infected OCLs were treated with IL-1a for 30 min, p65
was detected in most nuclei of the cells. Overexpression of
RasDN did not affect the kinetics of nuclear translocation
of NF-kB in OCLs (Fig. 4 D). Consistent with the results
of the immunocytochemistry, electrophoretic mobility shift
assay (EMSA) showed that NF-kB binding activity was
not impaired in RasDN-overexpressed OCLs (Fig. 4 C).
Modulation of NF-kB Activity Did Not Affect the 
Survival of OCLs
To further examine the role of NF-kB pathway in osteo-
clasts, we constructed adenovirus vectors encoding domi-
nant negative IKK2 (IKKDN) and constitutively active
IKK2 (IKKCA) with Flag tag, and investigated their effects
on OCLs. Fig. 5 A demonstrates the clear induction of
IKKDN and IKKCA in infected OCLs in an MOI-depen-
dent manner. Fig. 5 B shows that the degradation of IkB-a
induced by IL-1a treatment was strongly blocked by
IKKDN expression. Immunocytochemical studies showed
that IKKDN expression inhibited nuclear translocation of
p65 in IL-1a–stimulated OCLs (Fig. 5 D), and ,25% of
the nuclei of OCLs were positively stained for p65 even af-
ter 30 min of IL-1a stimulation. In contrast, .60% of the
nuclei of AxIkkCA-infected OCLs were positively stained
without any stimulation (Fig. 5 D). EMSA demonstrated
that NF-kB activation was inhibited in IKKDN-expressed
OCLs treated with IL-1a. Conversely, slight constitutive
NF-kB activation was observed in IKKCA-expressed OCLs
(Fig. 5 C). As shown in Fig. 6, neither IKKDN nor IKKCA
virus infection significantly changed the survival of OCLs
with or without IL-1a stimulation.
Figure 5. Adenovirus vector-induced
IKKDN or IKKCA expression in OCLs.
(A) OCLs formed on culture dishes
were noninfected or infected with
Ax1w1, AxIKKDN, or AxIKKCA at in-
dicated MOIs. After 24 h of infection,
OCLs were purified by enzymatic di-
gestion and lysed with TNE buffer.
The total cell lysate proteins were
Western blotted with anti–Flag anti-
body, which recognizes Flag-tagged
exogenous IKK2. The expression of
IKKDN or IKKCA increased in propor-
tion to the MOI of the recombinant
adenovirus, whereas the level of c-Src
was not significantly changed upon
IKKDN or IKKCA induction. (B) After
purification, Ax1w1- or AxIKKDN-
infected OCLs were preincubated for
20 min at 378C in aMEM without FBS
and further incubated in aMEM with
IL-1a for 15 min. The amount of IkB-a
was determined by Western blotting.
(C) Ax1w1, AxIKKDN, or AxIKKCA-
infected OCLs were incubated with 10 ng/ml IL-1a for the indicated time periods. Equivalent amounts of nuclear extract protein were
incubated with a radiolabeled probe containing NF-kB binding site. Activation of NF-kB was determined using EMSA. (D) Purified
IKKDN- or IKKCA-expressed OCLs were treated with IL-1a (10 ng/ml) for 30 or 0 min, respectively. Cells were fixed and incubated with
antibodies against p65 followed by Cy5-conjugated anti–rabbit immunoglobulins. IKKDN expression inhibited p65 nuclear translocation
in IL-1a–treated OCLs. In contrast, IKKCA induced constitutive nuclear localization of p65 in the absence of cell stimulation.Miyazaki et al. ERK and NF-kB in Osteoclasts 339
NF-kB Pathway Is Involved in Osteoclast Activation for 
Bone Resorption
We next examined the role of ERK pathways and NF-kB
pathways on bone-resorbing activity of OCLs using the
adenovirus vectors described above. This activity of OCLs
was quantified by measuring the pit area formed on den-
tine slices as previously reported (Tamura et al., 1993). To
minimize the influence of the different survival periods on
the pit formation by OCLs, we performed the pit assay af-
ter 12 h of culturing and the pit-forming activity is ex-
pressed as the area resorbed per osteoclast. As shown in
Fig. 7 A, neither RasDN nor MEKCA expression altered the
pit-forming activity of OCLs, indicating that the ERK
pathway is not involved in the bone-resorbing activity of
the individual OCL. In contrast, OCL pit-forming activity
was significantly inhibited by induction of IKKDN, whereas
overexpression of IKKCA enhanced it. Because IL-1a
strongly promotes not only the survival of osteoclasts, but
also their bone resorbing activity (Boyce et al., 1989), we
examined the effect of IKKDN expression on the bone-
resorbing activity promoted by IL-1a. As shown in Fig. 7
B, IL-1a treatment strongly enhanced the OCL pit-form-
ing activity, and inhibiting NF-kB activation by the IKKDN
virus significantly suppressed the pit-forming activity en-
hanced by IL-1a.
Colony-stimulating Factor 1 (CSF-1) Activates ERK, 
but Not NF-kB in OCLs
Because CSF-1 (also called macrophage colony-stimulat-
ing factor) has been reported to prolong the survival of
OCLs without upregulating their bone resorbing activity,
we examined the effect of CSF-1 treatment on ERK and
NF-kB activity in OCLs. As shown in the top panel of Fig.
8 A, ERK activation in response to CSF-1 was transient,
reaching the highest level after 2–15 min of stimulation
and returning to the basal level after 60 min. Stimulation
of ERK activity was not accompanied by a change in the
Figure 6. The effect of IKKDN and IKKCA expression on the sur-
vival of OCLs. After purification, OCLs infected Ax1w1, Ax-
IKKDN, or AxIKKCA were incubated with aMEM/10%FBS and
Ax1w1- or AxIKKDN-infected OCLs were incubated in the pres-
ence of IL-1a (10 ng/ml) for the indicated times. The number of
viable cells remaining at the different time points is shown as a
percentage of the cells at time zero.
Figure 7. Dentine-resorbing activity of OCLs expressing RasDN,
MEKCA, IKKDN, or IKKCA. (A) OCLs 24 h after the infection
were restored by digesting the collagen gel with 0.2% collagenase
for 20 min at 378C and an aliquot of the crude OCL preparation
was transferred onto dentine slices (f 5 mm) as well as on 96-well
culture plates and further cultured for 12 h. The resorbed area on
dentine slices was measured using an image analysis system, and
the number of TRAP-positive OCLs on culture plates was counted
by light microscopy. The bone-resorbing activity of the cells was
expressed as the resorbed area per osteoclast. The values are
means 6 SD (n 5 8). (one asterisk) Significantly less than control,
P , 0.05. (two asterisks) Significantly greater than control, P ,
0.05. (B) After the transfer onto dentine slices, Ax1w1- or Ax-
IKKDN-infected OCLs were further incubated for 12 h in the pres-
ence or absence of IL-1a (10 ng/ml). The pit-forming activity of
AxIKKDN-infected OCLs treated with IL-1a was significantly
lower than that of Ax1w1-infected OCLs treated with IL-1a (#P ,
0.01). The values are means 6 SD (n 5 8). ##Significantly greater
than Ax1w1-infected OCLs without IL-1a stimulation, P , 0.01.
Figure 8. The effects of CSF-1 treatment on OCLs. (A, top)
Time course of change in ERK activity in OCLs after stimulation
with CSF-1 (100 ng/ml). (middle) Western blot analysis of the ex-
pression of ERK protein. (bottom) Time course of change in the
protein level of IkB-a in CSF-1–treated OCLs. (B) OCLs were
incubated with CSF-1 for indicated time periods. Equivalent
amounts of nuclear extract protein were incubated with a radio-
labeled probe containing the NF-kB binding site. Activation of
NF-kB was determined using EMSA. IL-1a–treated OCLs (right
lane) were used as positive controls (PC). (C) After purification,
OCLs were incubated with aMEM/10% in the presence or ab-
sence of CSF-1 for the indicated times. The number of viable
cells remaining at different time points is shown as a percentage
of the cells at time zero. (D) After the transfer onto dentine
slices, OCLs were further incubated for 12 h in the presence or
absence of CSF-1 (100 ng/ml). CSF-1 stimulation did not alter the
OCL pit-forming activity. The values are means 6 SD (n 5 8).The Journal of Cell Biology, Volume 148, 2000 340
expression level of ERK protein (Fig. 8 A, middle). As
previously reported (Fuller et al., 1993; Jimi et al., 1995),
CSF-1 treatment strongly promoted the survival of OCLs
(Fig. 8 C). On the other hand, CSF-1 did not alter the ex-
pression level of IkB-a (Fig. 8 A, bottom) and activate
NF-kB (Fig. 8 B). In addition, OCL bone-resorbing activ-
ity remained unchanged despite CSF-1 stimulation (Fig. 8
D). These results strongly support our findings that ERK
and NF-kB pathways are involved in osteoclast survival
and activation for bone resorption, respectively.
Discussion
The Ras superfamily of GTPases is implicated in a number
of cellular physiological processes including cell prolifera-
tion and differentiation, and plays important roles in the
organization of cellular architecture and regulation of
membrane dynamism in addition to cell cycle control
(Bourne et al., 1990; Bollag and McCormick, 1991; Kaziro
et al., 1991). Recently, Luckman et al. (1998) reported that
the nitrogen-containing bisphosphonates alendronate, iban-
dronate, and risedronate, which cause apoptosis in osteo-
clasts and suppress their bone-resorbing activity, inhibit
posttranslational modification (prenylation) of proteins
with farnesyl or geranylgeranyl isoprenoid groups, includ-
ing the Ras superfamily of GTPases. Further studies per-
formed by Fisher et al. (1999) demonstrated that alendronate
acts directly on osteoclasts and interferes with the genera-
tion of geranylgeranyl diphosphate by inhibiting enzymes in
the cholesterol biosynthesis pathway, resulting in the sup-
pression of osteoclast function. These findings suggest the
critical role of the Ras superfamily in this function.
The pleiotropic functions of the Ras protein are now ex-
plained by its capability to activate multiple downstream
pathways (Koide et al., 1993; Moodie et al., 1993; Rod-
riguez-Viciana et al., 1994; Van Aelst et al., 1993, 1994;
Vojtek et al., 1993). One of the most important signaling
cascades lying downstream of Ras is the MAPK cascade,
which is activated via the Ras–Raf interaction. This inter-
action induces the membrane translocation and activation
of Raf, and activated Raf phosphorylates tyrosine/threo-
nine kinase MEK, which in turn phosphorylates ERK. In
the present study, we demonstrated the essential role of
Ras/ERK pathways in the survival of osteoclasts. First, ad-
enovirus vector carrying a dominant negative mutant of
Ras (AxRasDN) suppressed ERK activity in OCLs and pro-
moted the apoptosis of OCLs. A similar effect was observed
using a MEK inhibitor, PD98059. Second, expression of con-
stitutively active MEK1-induced sustained stimulation of
ERK in OCLs and dramatically promoted their survival,
and the apoptosis-inducing effect of AxRasDN was com-
pletely rescued by coinfection with AxMEKCA. Finally, IL-
1a, which strongly promotes OCL survival, rapidly stim-
ulates ERK activation in OCLs. It should be noted that
overexpression of RasDN only partially inhibited the ERK
activation and suppressed the prolonged survival induced
by IL-1a, whereas PD98059 strongly eliminated the effect
of IL-1a (data not shown), suggesting that IL-1a stimu-
lates ERK activity via Ras-independent pathways as well.
These results clearly demonstrate that ERK activation is
indispensable for the survival of osteoclasts, and that Ras
is at least partially involved in this process.
It remains elusive how ERK activation stimulates OCL
survival. In fibroblasts, ERK activation is followed by
phosphorylation of transcription factors and induction of
immediate early gene expression. The dimeric transcrip-
tion factor AP-1 (activator protein-1) is a major target of
cell growth, differentiation, and stress signaling pathways
(Angel and Karin, 1991; Karin and Hunter, 1995; Whit-
marsh and Davis, 1996). AP-1 consists of various combina-
tions of Fos and Jun family members that dimerize via a
leucine zipper domain and bind to DNA via an adjacent
basic region (Landschulz et al., 1988; Gentz et al., 1989;
Kouzarides and Ziff, 1989). The Fos family consists of four
gene products (c-Fos, FosB, Fra-1, and Fra-2), whereas the
Jun family is made up of three gene products (c-Jun, JunB,
and JunD). We also found that sustained stimulation of
ERK in OCLs by MEKCA expression as well as IL-1a
stimulation increased c-Fos, Fra-2, c-Jun, and JunB ex-
pression (data not shown), suggesting that AP-1 activation
may be involved in the survival signaling in osteoclasts.
Further study will be necessary to elucidate the detail of
osteoclast survival signaling.
Jimi et al. (1998) recently reported that the activation of
NF-kB is involved in the survival of osteoclasts promoted
by IL-1a. They clearly showed the nuclear translocation of
NF-kB and degradation of IkB in OCLs in response to IL-1a
treatment. The survival of OCLs supported by IL-1a was
suppressed by pretreatment with proteasome inhibitors,
which inhibits NF-kB activation by preventing IkB degra-
dation, or with antisense oligonucleotides to NF-kB com-
ponents (Jimi et al., 1998). In contrast to their results, we
were unable to show the effect of NF-kB on the survival of
OCLs. Consistent with the previous report, IL-1a treat-
ment induced rapid nuclear translocation of NF-kB in
OCLs and degradation of IkB. However, overexpression
of neither RasDN nor MEKCA changed the localization of
NF-kB in the presence or absence of IL-1a. In addition,
either inhibition of NF-kB activity by overexpression of
dominant negative IKK (IKKDN) or sustained activa-
tion of NF-kB by transducing constitutively active IKK
(IKKCA) had little effect on the survival of OCLs with or
without IL-1a stimulation. We cannot fully explain the
reason for the discrepancy between our results and those
of the previous report, but it is possible that proteasome
inhibitors and antisense oligonucleotides may possess
some undesirable effects on OCLs unrelated to NF-kB in-
hibition.
However, NF-kB has an important role in the bone-
resorbing activity of osteoclasts because adenovirus vector-
induced IKKDN expression significantly suppressed the
pit-forming activity of OCLs and IKKCA expression en-
hanced it, although these two viruses had no effect on
OCL survival. Members of the TNF receptor family and
the IL-1 receptor associated either directly or indirectly
with TNF receptor-associated factors (TRAFs), adaptor
proteins that recruit and activate downstream signaling
transducers (Rothe et al., 1994). TRAF6 is a newly identi-
fied member of TRAF, which is not involved in TNF sig-
naling but in IL-1 signaling (Cao et al., 1996; Darnay et al.,
1998; Galibert et al., 1998). Not only does TRAF6 activate
NF-kB by signaling via NIK and IKK, but it also activates
ERK in a Ras-independent manner (Kashiwada et al.,
1998). A recent study on TRAF6 knockout mice demon-Miyazaki et al. ERK and NF-kB in Osteoclasts 341
strated the essential role of TRAF6 on the activation of
osteoclasts (Lomaga et al., 1999). Taken together, it is
likely that IL-1a can promote survival and activity of os-
teoclasts simultaneously via ERK and NF-kB activation,
both of which are mediated by TRAF6. Our present study
proposes the reciprocal role of ERK and NF-kB pathways
in the survival and activation of osteoclasts. Further inves-
tigation of these pathways in osteoclasts will give us new
insight into the molecular mechanism regulating bone re-
sorption.
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